An experimental study involving 90 heavy drinkers found promising results.
- A single dose of ketamine has been shown reduce cravings for alcohol in heavy drinkers.
- Ninety drinkers took part in the experimental study; the ketamine groups fared best.
- This research on addiction follows in the wake of a ketamine derivative being used for treatment-resistant depression.
While legalization has benefits, a new study suggests it may have one big drawback.
- A new study finds that rates of marijuana use and addiction have gone up in states that have recently legalized the drug.
- The problem was most severe for those over age of 26, with cases of addiction rising by a third.
- The findings complicate the debate around legalization.
FieldTrip is advancing the realm of clinical psychedelic testing.
- FieldTrip Ventures is opening the world's first psilocybin research center at the University of the West Indies.
- More research on magic mushrooms follows mounting evidence of the efficacy of ketamine and MDMA.
- Ronan Levy of FieldTrip believes psychedelics could help treat a wide range of mental health conditions.
What's next for the nation's opioid cases?
- Johnson & Johnson has been ordered to pay the state of Oklahoma $572 million for downplaying the dangers and overselling the benefits of opioids.
- The state's lawyers argued that Johnson & Johnson had violated a public nuisance law, which concerns injuries to public health.
- The first federal trial in the opioid crisis is scheduled for October. It's likely that the Oklahoma verdict doesn't help drug manufacturers and distributors.
Yet another study shows the potential efficacy of psychedelics in treating addiction.
- MDMA could help alcoholics break their addiction (and not relapse) suggests a new study in the UK.
- Ketamine became the first FDA-sanctioned psychedelic for use in treating depression earlier this year.
- The Multidisciplinary Association for Psychedelic Studies (MAPS) organization hopes to have legally prescribed MDMA on the shelves by 2021.